Skip to content
10-Q

Quarterly Report

Astria Therapeutics, Inc.

0001410578-24-000691

← back to feed
Filed
May 9, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 30, 2024 54.91M sh
Short Term Investments Q1 2024 · Mar 31, 2024 $197.9M
Short Term Investments Q1 2024 · Dec 31, 2023 $71M
Current Liabilities Q1 2024 · Mar 31, 2024 $11.07M
Current Liabilities Q1 2024 · Dec 31, 2023 $11.55M
Total Liabilities Q1 2024 · Mar 31, 2024 $11.07M
Total Liabilities Q1 2024 · Dec 31, 2023 $11.55M
Current Assets Q1 2024 · Mar 31, 2024 $374.52M
Current Assets Q1 2024 · Dec 31, 2023 $250.94M
Total Assets Q1 2024 · Mar 31, 2024 $378.81M
Total Assets Q1 2024 · Dec 31, 2023 $254.67M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $175.53M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $202.3M
Shares Diluted Q1 2024 · Mar 31, 2023 27.94M sh
Capex Q1 2024 · Mar 31, 2023 $5K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$13.25M
Stockholders Equity Q1 2024 · Mar 31, 2023 $211.36M
Stockholders Equity Q1 2024 · Dec 31, 2022 $221.22M
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.40
Eps Basic Q1 2024 · Mar 31, 2023 −$0.40
Sga Expense Q1 2024 · Mar 31, 2023 $5.46M
Net Income Q1 2024 · Mar 31, 2023 −$11.19M
Operating Income Q1 2024 · Mar 31, 2023 −$13.49M